NAV

Cusatuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Cusatuzumab is a CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies.

Generic Name
Cusatuzumab
DrugBank Accession Number
DB15100
Background

CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.2

Cusatuzumab is a humanized IgG1 antibody targeted against CD70.1 It is currently being investigated in the Phase 2 CULMINATE trial, in combination with azacitidine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in patients unsuitable for chemotherapy.1,3

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Cusatuzumab
External IDs
  • ARGX-110
  • JNJ-74494550
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

CD70 is transiently expressed on activated lymphocytes and mature dendritic cells, where it serves as a ligand for the CD27 receptor.2 The CD70-CD27 interaction results in the downstream activation of the NF-κB pathway responsible for cell proliferation and survival. The overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological tumors - elevated urinary concentrations of soluble CD27 (sCD27), a byproduct resulting from the CD70-CD27 interaction, are correlated with a poorer prognosis in patients with non-Hodgkin lymphoma (NHL), Waldenström macroglobulinemia, and acute lymphoblastic leukemia (ALL).2

CD70 may also be involved in creating a tumor microenvironment that facilitates immune system evasion via the recruitment of regulatory T-cells.2,1

Cusatuzumab is a humanized IgG1 monoclonal antibody targeted against CD70. In binding to CD70, cusatuzumab blocks the CD70-CD27 signaling that results in the proliferation of malignant cells and prevents the formation of sCD27.3 In addition, cusatuzumab may exert some efficacy via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC).3

TargetActionsOrganism
ACD70 antigen
antibody
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
RR5U4UFJ8L
CAS number
1864871-20-4

References

General References
  1. Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476. [Article]
  2. Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ: ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6. [Article]
  3. Argenx Drug Pipeline: Cusatuzumab [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAcute Myeloid Leukemia1
2Not Yet RecruitingTreatmentAcute Myeloid Leukemia1
2WithdrawnTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia1
1CompletedTreatmentAcute Myeloid Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. CD70 antigen
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antibody
General Function
Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.
Specific Function
Cytokine activity
Gene Name
CD70
Uniprot ID
P32970
Uniprot Name
CD70 antigen
Molecular Weight
21118.19 Da
References
  1. Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476. [Article]

Drug created at May 20, 2019 14:49 / Updated at November 11, 2021 15:59